



DECLARATION OF CONFORMITY

Manufacturer: Invivoscribe, Inc.
10222 Barnes Canyon Rd. Bldg 1
San Diego, California 92121
United States of America

Authorized Representative: Invivoscribe Technologies, SARL
327 Boulevard Michelet
13009 Marseille
FRANCE
Phone: +33 (0)4 42 01 78 10
Fax : +33 (0)4 88 56 22 89


Family Name: LeukoStrat®

Device Trade Name: FLT3 Mutation Assay

Catalog #	Device	Quantity	Basic UDI-DI	GTIN
9-412-0091	LeukoStrat® FLT3 Mutation Assay 2.0 – ABI Detection	33 Reactions	08100227394120091SA	00810022730034

I, the undersigned, hereby declare that the *in-vitro* diagnostic medical devices specified above conform to the European Directive 98/79/EC, *In vitro* Diagnostic Medical Device Directive, Annex III.

Date of Validity: 17 May 2022

By: 

Jason Gerhold
Global Director of Quality, Regulatory and Clinical Affairs
Invivoscribe, Inc.
10222 Barnes Canyon Rd. Bldg 1
San Diego, California 92121
USA